医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Replicor Discloses Updated REP 401 Clinical Data at APASL 2017

2017年02月10日 PM10:00
このエントリーをはてなブックマークに追加


 

MONTREAL

Replicor Inc., a privately held biopharmaceutical company targeting a cure for chronic hepatitis B and D patients, today announced that an updated interim analysis from its latest REP 401 clinical trial has been selected by the Asia Pacific Association for the Study of Liver (APASL) for oral presentation at its annual meeting to be held February 15-19, 2017 in Shanghai, China.

The REP 401 protocol (NCT02565719) is a randomized, controlled trial assessing the safety and efficacy of its first in class HBsAg release inhibitor, REP 2139 and a REP 2139 derivative with improved plasma and tissue clearance (REP 2165) in combination with tenofovir disoproxil fumarate (TDF) and pegylated interferon alpha-2a (peg-IFN) in treatment naïve patients with chronic HBeAg negative HBV infection.

The updated clinical analysis, to be presented on Feb 18th (OP 116) will include substantially longer exposure analysis in experimental and control groups and include for the first initial analysis of antiviral response when NAP therapy is added 24 weeks after peg-IFN therapy in crossover patients in the adaptive comparator control arm.

Replicor’s presentation from APASL 2017 will be available on the company’s website following its disclosure at the meeting at www.replicor.com/science/conference-presentations. For further information about the 2017 APASL Meeting visit: http://www.apasl2017.org/#/.

About Replicor

Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV co-infection. For further information about Replicor please visit our website at www.replicor.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170210005095/en/

CONTACT

Replicor
Media Contact:
Natacha Dorget,
514-733-1998
ndorget@replicor.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • オクタファルマ:重度血友病Aの未治療患者がoctanate®を使用するとインヒビター発現率が低減
  • Octapharma:罹患重症血友病A的既往未曾治疗患者(PUP)使用octanate®后,抑制因子的发生率降低
  • Takeda Recognized as a Global 100 Most Sustainable Corporation for Third Consecutive Year
  • 武田薬品:「世界で最も持続可能な100社」に3年連続で選出
  • GI Dynamics Announces AUD $2.05m Private Placement and Close of First Tranche of AUD ~$1m